Royalty Report: Drugs, ribonucleic acid, Therapeutic – Collection: 204368

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • ribonucleic acid
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 204368

License Grant
Licensor grants to the Licensee an exclusive world-wide license under the Patent Rights in order to develop, make, have made, use and sell Licensed Products, with the right to sub-license.
License Property
The Invention shall mean the substituted porphyrin compounds and methods of their use,  invented in part, a result of research covered under the First Agreement and designated as Licensor Technology ID No. 2000-15.
Field of Use
The present invention relates to methods of protecting against the deleterious effects of oxidants, particularly, superoxide radicals, hydrogen peroxide and peroxynitrite, and to methods of preventing and treating diseases and disorders that involve or result from oxidant stress.

Oxidative stress is an imbalance between free radicals and antioxidants in your body. Free radicals are oxygen-containing molecules with an uneven number of electrons. The uneven number allows them to easily react with other molecules.

IPSCIO Record ID: 294284

License Grant
For the Option the German Licensor grants the right to request from Licensor for each of the  Licensee targets an option on a non-exclusive and worldwide licence for Licensor IP with the right to sub-license at terms consistent with this Agreement to evaluate, develop and commercialise therapeutic atuRNAis inhibiting the specific Licensee Target agreed upon, the QBI Option.

For the License, upon exercise of each specific option the German Licensor shall grant a non-exclusive license under German IP in accordance with the terms and conditions specified.  Licensor agrees to grant a non-exclusive and worldwide license with the right to sub-license at terms and conditions consistent with this Agreement under the Licensor IP and the know-how relating to the atuRNAi(s) to research, develop, have developed, manufacture, have manufactured, market and sell Licensee Products.

License Property
Licensor IP means the Licensor patents and patent applications as of the date of this Agreement.

atuRNAi(s) shall mean the siRNAs developed by or for Licensor and supplied to Licensee under this Agreement as potential inhibitors of certain molecular drug targets for therapeutic intervention.

Licensee IP means the present and future Patent Rights and Know-How owned by Licensee and directed to the [polypeptides, to nucleic acids encoding the polypeptides, antibodies to the polypeptides, antisense and siRNAJ to the Licensee Target genes and methods of treatment of diseases using these, including but not limited to rights to patents and patent applications.

Licensee Products means Products and Drug Products for the treatment of human diseases covered by Licensee IP.

The property includes Patent application EP 04010700.05 describing the use of lipids in formulations to deliver oligonucleotides into cells and tissues and all equivalent and derived applications including EP 02017601.2], and, PCT application number WO 2004/015107 and all equivalent/derived applications including US Provisional Application 60/402,541, the Licensors core technology patent application.

Field of Use
The field of use is for the treatment of human diseases covered by Licensees IP.  The Licensees primary focus has been for the treatment of diseases associated with oxidative stress and ischemic injury.

Oxidative stress is an imbalance between free radicals and antioxidants in your body. Free radicals are oxygen-containing molecules with an uneven number of electrons. The uneven number allows them to easily react with other molecules.

Ischemic injury is caused by diminished or absent blood flow. The main mechanism of injury in ischemia is hypoxia (as described above).

IPSCIO Record ID: 25783

License Grant
The Licensor granted the Licensee a Non-exclusive License to research, develop, market, distribute, and sell Luteolin and related bioflavonoid-based products covered by Patent, number 6,774,142 Inhibition by 3-Deoxyflavonoids of T-Lyrnphocyte Activation and Therapies Related Thereto.
License Property
In consideration for the Non-exclusive Patent License Agreement, Licensee shall manufacture and deliver to Licensor Five Thousand  bottles of 10 mg LutiMax tablets, bottled and labeled as directed by Licensor.  This License shall not be assignable by Licensee without the prior written consent of Licensor.

Luteolin is the active ingredient in LutiMax.  Luteolin is a Super-Nutrient from a class of naturally occurring molecules known as bioflavonoids.  Luteolin neutralizes free radicals such as superoxide, the hydroxyl radical, and other reactive oxygen compounds to help reduce oxidative stress and may help reduce inflammation, regulate hyperactive immune systems, and promote healthy carbohydrate metabolism.

Field of Use
The rights apply to help reduce oxidative stress and may help reduce inflammation, regulate hyperactive immune systems, and promote healthy carbohydrate metabolism.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.